No abstract

Study Design Prospective clinical study. Purpose The present study aimed to examine the neurological recovery pattern in cervical spondylotic myelopathy (CSM) after anterior cervical decompression and compare it with the existing reports in the literature. Overview of Literature Neurological recovery and regression of myelopathy symptoms is an important factor that determines the outcomes of surgical decompression. The present findings contribute to the literature on the pattern of neurological recovery and patient prognosis with respect to the resolution of myelopathy symptoms after surgery. Methods This prospective study was conducted in Government Medical College in Jammu, North India between November 2012 and October 2014, a total of 30 consecutive patients with CSM were included and treated with anterior decompression and stabilization. They were prospectively followed up for 1 year and were evaluated for their neurological recovery pattern. The postoperative outcome was evaluated using the modified Japanese Orthopaedic Association (mJOA) score. The recovery rate was calculated using Hirabayashi’s method. The JOA score was assessed before the operation and postoperatively at 1 week, 2 weeks, 1 month, 3 months, 4 months, 6 months, and 1 year. Results The postoperative mJOA score was 0 in the 1st month, 12.90±3.57 in the 3rd month, 13.50±3.55 in the 4th month, 14.63±3.62 in the 6th month, and 14.9±3.24 at the final follow-up of 1 year. The average recovery rate during the 1st month follow-up was 0%, and that during the 3rd month follow-up was 12.91% with a range of 0%–50%. The average recovery rate during the 4th month was 32.5%, with a range of 0%–60%, while that during the 6th month was 72.83%, with a range of 0%–100%. The average recovery rate during the final follow-up of 1 year was 54.3%. Conclusions Neurological recovery after surgical decompression starts from the 3rd postoperative month and progresses until the 6th postoperative month; thereafter, it gradually plateaus over the subsequent 6 months until it steadies. Symptom duration is an important factor that requires consideration while determining postoperative neurological recovery.

Polytrauma is a major cause of morbidity and mortality in both developed and developing countries. The term "Polytrauma" is mainly used to describe blunt trauma patients whose injuries involve multiple body regions or cavities, compromise patient's physiology and potentially cause dysfunction of uninjured organs. This study about epidemiology of fractures in polytrauma patients was carried out in emergency of Orthopaedics Department, Government Medical College, Jammu. The study was done for a duration of one year. Data was collected related to age, sex, mode of injury, date, time of injury and admission, pattern of fractures, associated injuries as per in the standard protocol proforma. Then various mechanisms of trauma were correlated to the type of injuries, to define pattern of injuries encountered in various accidents in polytrauma victims and then analysis of data was done.

Post-surgical infections constitutes a major cause of morbidity and mortality in postoperative patients in orthopaedics. Most of these are hospital acquired and organisms being resistant to major antibiotics and patients are not in a condition to be discharged from hospital. The aim of the present study was to analyze the role of Tranexaemic acid in prevention of wound infection in postoperative patients. A total of 120 patients were taken of which 30 each were operated for spine, intertrochanteric fractures, bipolar hemiarthroplasty and general orthopaedics (Forearm plating, distal humeral plating, philos). Age of the patient were taken between 18 to 65 years. Males formed about 60% of the patients. Duration from injury to surgery was 3.56 days. Two patients out of 60 on tranexaemic acid were infected whereas 4 out of 60 patients who were not given the medicine were infected. The drug proves to be also effective in reducing wound dehiscence rate, need of prolonged antibiotics and thus overall reduces the postoperative morbidity in patients.

No abstract